Skip to content

Aura Biosciences, Inc. AURA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$101.3M-41.9%
Nuvation Bio logo
Nuvation BioNUVB
$3.91M+107%
Immunome logo
ImmunomeIMNM
-$53.84M-29.1%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$189.52M-200%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$46.14M-11.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$661.6M-21.8%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Aura Biosciences, Inc. (AURA) reported comprehensive income (loss), net of tax, attributable to parent of -$33.79M in Q1 2026.
How has Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 22.2% year-over-year, from -$27.64M to -$33.79M.
What is the long-term trend for Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 29.8% compound annual growth rate (CAGR), from -$37.58M to -$106.56M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
The total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. This metric provides a holistic view of the company's financial performance by incorporating unrealized gains or losses that are excluded from traditional net income. It serves as a comprehensive measure of the change in the company's net worth over a specific period.